Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Summary

The purpose of the study is to evaluate the safety and efficacy of zilucoplan (RA101495) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.

Timeline

Start

2017-03-08

Primary completion

2018-03-28

Completion

2018-03-28

Drugs

Indications